Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results

Core Insights - Belite Bio, Inc is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs [3] - The company will host a webcast on August 11, 2025, to discuss its financial results and provide a business update for Q2 2025 [1][2] Company Overview - Belite Bio targets degenerative retinal diseases such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD) [3] - The lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye and is currently in multiple clinical trials, including Phase 3 studies [3]